<DOC>
	<DOCNO>NCT02322099</DOCNO>
	<brief_summary>Antiretroviral therapy ( ART ) initiation associate significant loss bone mineral density ( BMD ) , characterise increase bone turnover , largely limit first 48 week therapy . Bisphosphonates , alendronate , decrease bone turnover limit loss bone mineral density . This study aim determine short course treatment oral bisphosphonate alendronate limit loss bone mineral density associate initiation ART HIV-1 infect , antiretroviral naive , adult subject .</brief_summary>
	<brief_title>Alendronate Prevention AntiRetroviral Therapy-associated Bone Loss</brief_title>
	<detailed_description>Multi-centre , prospective , randomised , double-blind , placebo-controlled trial 50 week . The aim study include : 1 . To determine short-course treatment alendronate versus placebo combine calcium vitamin D , initiate 2 week prior start ART prevent loss BMD 48 week follow-up post ART initiation . 2 . To explore effect alendronate bone turnover set ART initiation . 3 . To determine factor , choice ART , impact protective effect alendronate prevent BMD loss . 4 . To determine relationship change bone turnover marker , vitamin D , parathyroid hormone calcium level . 5 . To explore pathogenesis BMD loss initiation ART investigate relationship change immune function ( T-cells B-cells subset ) , bone turnover BMD .</detailed_description>
	<mesh_term>Bone Demineralization , Pathologic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>male &gt; 30 year old female &gt; 35 year old HIV1 antibody positive antiretroviral therapy na√Øve presume achieved peak bone mass eligible initiation antiretroviral therapy opinion investigator able provide write , informed consent subject unable comply study protocol unable stand/sit upright least 30 minute history osteoporosis history fragility fracture previous femoral fracture chronic renal failure hypocalcemia hypercalcemia screen history Paget 's disease know primary hyperparathyroidism previous treatment allergy ( include hypersensitivity ) bisphosphonates recent history ( past 12 month ) peptic duodenal ulcer oesophagitis , aspiration abnormality oesophagus current therapy prescribe calcium vitamin D preparation ( overthecounter multivitamin preparation ) current therapy aspirin regularly prescribe nonsteroidal antiinflammatory drug recent dental work ( within past 3 month ) poor oral hygiene ( judged opinion investigator ) recent ( within past three month ) significant steroid exposure female subject : pregnancy screening , plan future pregnancy unwilling take measure avoid pregnancy duration study investigator 's opinion , necessity initiate ART within preART study window period hepatitis B hepatitis C coinfection active illness ( include AIDS illness ) opinion investigator precludes participation study subject concurrently enrol another clinical trial investigational medical product</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>human immunodeficiency virus</keyword>
	<keyword>bone disease</keyword>
	<keyword>osteopenia</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>fracture</keyword>
	<keyword>bone turnover</keyword>
	<keyword>alendronate</keyword>
	<keyword>antiretroviral</keyword>
</DOC>